Home > Hubert Fernandez, IAPRD 2018 – Highlights from the Scientific Program Executive Committee Chair
Parkinson's Disease

Hubert Fernandez, IAPRD 2018 – Highlights from the Scientific Program Executive Committee Chair

Published Online: September 20th 2018

Chair of the IAPRD 2018 Scientific Program Executive Committee, Hubert Fernandez (Cleveland Clinic, Cleveland, OH, US), discusses identification of patients with Parkinson’s disease (PD) at risk of cognitive decline, the advantages of levodopa-carbidopa intestinal gel in advanced PD, recent exciting advances in PD therapy, as well as strengths and highlights of this year’s meeting.

Questions

Part 1

1. How can we best identify patients with Parkinson’s disease (PD) at risk of cognitive decline? (0:14)
2. What are the advantages of levodopa-carbidopa intestinal gel in advanced PD? (3:00)

Part 2

1. What do you consider the most exciting advances in PD therapy in recent years? (0:14)
2. What do consider are the greatest strengths of the IAPRD meeting? (3:57)
3. What do you expect to be the highlights of IAPRD 2018? (5:08)

Filmed at the XXII World Congress on Parkinson’s Diseases and Related Disorders (IAPRD), Lyon, France, August 2018.

Speaker disclosure (over the past 12 months).

Grants/Research Support: Dr. Fernandez has received research support from Abbvie, Acadia, Teva, Biotie/Acorda Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Synosia, but has no owner interest in any pharmaceutical company.

Honoraria: Dr. Fernandez has received honoraria from Prime Education Inc. International Parkinson and Movement Disorders Society, Carling Communications, Medscape, as a speaker in CME events. Dr. Fernandez has received honoraria from AbbVie, Biogen, GE Health Care, Inventiv, Kyowa Hakko Kirin, Lundbeck, Medscape, Merz Pharmaceuticals, Voyager, Sunovion, and Pfizer Pharmaceuticals, as a consultant.

Royalty: Dr. Fernandez has received royalty payments from Demos Publishing for serving as a book author/editor.

Contractual Services: The Cleveland Clinic has a contract with Teva for Dr. Fernandez’ role as a Co-Principal Investigator in SD-809 Tardive Dyskinesia global studies. Dr. Fernandez also serves as a member of the publication committee for Acorda Pharmaceuticals but does not receive any personal compensation for these.

Other: Dr. Fernandez has received a stipend from International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site.

Share this Video
Related Videos In Parkinson's Disease
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72